Contineum Therapeutics/$CTNM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Contineum Therapeutics
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
Ticker
$CTNM
Sector
Primary listing
Employees
51
Headquarters
Website
CTNM Metrics
BasicAdvanced
$568m
-
-$1.91
0.70
-
Price and volume
Market cap
$568m
Beta
0.7
52-week high
$16.91
52-week low
$3.72
Average daily volume
422k
Financial strength
Current ratio
38
Quick ratio
37.003
Long term debt to equity
1.86
Total debt to equity
2.781
Profitability
EBITDA (TTM)
-66.525
Management effectiveness
Return on assets (TTM)
-18.18%
Return on equity (TTM)
-26.88%
Valuation
Price to book
2.27
Price to tangible book (TTM)
2.27
Price to free cash flow (TTM)
-8.053
Free cash flow yield (TTM)
-12.42%
Free cash flow per share (TTM)
-1.886
Growth
Earnings per share change (TTM)
-3.21%
What the Analysts think about CTNM
Analyst ratings (Buy, Hold, Sell) for Contineum Therapeutics stock.
CTNM Financial Performance
Revenues and expenses
CTNM Earnings Performance
Company profitability
CTNM News
AllArticlesVideos
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
Business Wire·2 weeks ago
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
Business Wire·1 month ago
Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential
MarketBeat·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.